Purpose: TiS 2 -HSA-FA, a nanoagent based on titanium disulfide (TiS 2 ), human serum albumin (HSA), and folic acid (FA), was synthesized for potential use in synergistic photothermal/radiation therapy for colon cancer. Methods: TiS 2 nanosheets were synthesized through a HSA-assisted exfoliation method and then modified with PEGylated FA. The morphology, size, zeta potential, stability, cellular uptake, cytotoxicity, biodistribution, and in vitro and in vivo biocompatibility of the nanoparticles as well as their suitability for synergistic photothermal/radiation colon cancer therapy were investigated. Results: The as-synthesized TiS 2 -HSA-FA nanoparticles showed excellent physiological stability, as well as high absorption values in the near-infrared (NIR) and X-ray regions, giving them superb activity as a photothermal and radiation sensitizer. In vitro and in vivo experiments indicated that TiS 2 -HSA-FA showed high tumor targeting selectivity, blood circulation time, biocompatibility, and suitability for synergistic tumor photothermal radiotherapy. Conclusion: A multifunctional nanoplatform based on TiS 2 was developed and found to be potentially suitable for synergistic photothermal/radiation therapy for colon cancer.
Introduction
Although anti-tumor therapeutics have greatly improved in recent decades, malignant tumors are still a major threat to human beings' health worldwide. 1, 2 One of the most commonly used treatment strategies is radiotherapy (RT), in which tumors are exposed to ionizing radiation such as X-rays in an attempt to produce necrosis of tumor tissue through DNA damage and generation of reactive oxygen species. [3] [4] [5] However, in practice, RT has several drawbacks. One is that it can harm normal tissue and thereby induce acute side effects such as nausea and vomiting, hair loss, etc. 6, 7 Another is that considerable dose must be used to ensure that all tumor cells are killed, and yet X-ray irradiation has no tumor specificity. This necessitates excessively large radiation doses, inevitably causing injury to healthy tissues. To overcome these drawbacks, a series of radio-sensitizers such as the two-dimensional (2D) layered transition metal dichalcogenides (TMDs) (MoS 2 , WS 2 , MoSe 2 , and ReS 2 ) and other inorganic materials have been prepared. [8] [9] [10] [11] [12] [13] Most TMDs were reported to contain high-Z elements that can act as radio-sensitizers to promote the cancer RT effect by absorbing X-rays and concentrating the radiation dose within tumors. [14] [15] [16] For example, Shen and co-authors have prepared uniform ultrathin rhenium disulfide nanosheets for photothermal RT. 16 However, the hypoxic environment inside tumors is still considered a major challenge for successful use of radio-sensitizers in RT. 17, 18 Photothermal therapy (PTT) has attracted substantial interest of late, as an alternative tumor treatment strategy. 19, 20 It is minimally invasive, and its high specificity means minimal side effects in normal tissues. PTT relies on photothermal agents to convert absorbed light energy into heat to kill tumor cells. [21] [22] [23] Recently, various nanomaterials such as organic small molecules, 24, 25 TMDs-based nanocomposites, 19, 26 protein-based nanoparticles, 27, 28 etc. have been developed as PTT nanoagents. [29] [30] [31] Among these, TMD-based nanoagents have demonstrated great potential for PTT because of their strong absorbance in the near IR (NIR) region and their large specific surface area which facilitates their functional modification. In addition, under NIR laser irradiation, TMD-based nanoagents can increase intratumor blood circulation, thereby facilitating oxygen availability inside the tumor, which could facilitate the RT effect. 16, 32, 33 It is, therefore, thought that some type of TMD nanomaterial could be found which could act as an "all in one" nanoagent, perfectly combining RT and PTT for optimal therapeutic effect. In this work, we prepared a new multifunctional nanoagent for combined PTT and RT, using tumor-targeted molecule FA and PEG modification of albumin exfoliated TiS 2 nanosheets (TiS 2 -HSA-FA). TiS 2 , as a new member of the TMD family, has been reported to have a high NIR absorbance which makes it an attractive candidate for PTT. [34] [35] [36] Given its potential as a dual-modality therapy nanoagent, its efficacy as a radio-sensitizer is investigated here for the first time. In vitro synergistic PTT/RT CT26 cells were treated with different concentration of TiS 2 -HSA and TiS 2 -HSA-FA (0, 10, 30, 50, 100, 150 μg/ mL) and were cultured in 37°C incubator for 5 hrs. After washing the nanoparticles outside the cells, they were irradiated with NIR irradiation (808 nm laser at a power density of 0.8 W/cm 2 for 5 mins) or RT (5Gy), or their combination. And then, the treated cells were further cultured for 24 hrs. During the 5 mins NIR irradiation, a handheld thermal camera (Ti27, Fluke, USA) was used to record the temperature change of the cells. The cell death rate was calculated using a typical CCK-8 assay.
As above, the cells were treated with TiS 2 -HSA and TiS 2 -HSA-FA, following by irradiation with NIR irradiation and Xray at the same condition. According to the previous literatures, the cells were further stained with calcein-AM/PI and γ-H2AX, respectively, to evaluate the cell death. The fluorescence signal of stained cells was observed by a confocal laser scanning microscope (LSM 510 NLO META, Zeiss, Germany).
Animal model
We have revised the ethics statement: All animal experiments were strictly complied with the guideline of Animal Protection and Care Committee of Sichuan University. All animal experimental procedures involved in this work were approved by the Ethics Committee of Sichuan University. For CT26 tumor xenograft models, 10 6 CT26 cells in 150 μL PBS were subcutaneously injected into the right back of mice. After 7-10 days of inoculation, the tumor size was detected by a caliper. . RT applied 5 Gy X-ray for 5 mins. The temperature change of the tumor region when irradiated by NIR was recorded using an infrared thermal camera. Every three days treatment, the tumor size was recorded and the tumor volume was calculated according to the equation: V = length × width 2 /2. The relative tumor volume was calculated as V/V 0 (V: current volume, V 0 : initial tumor volume). After the whole treatment, the major organs of these mice were collected for hematoxylin and eosin (H&E) staining. In addition, the blood was collected and the index including white blood cell (WBC), red blood cells (RBC), hemoglobin (HGB), mean corpuscular hemoglobin (MCH), hematocrit (HCT), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), and platelet (PLT) were detected.
In vivo synergistic PTT/RT

Statistical analysis
All data were presented as mean with standard deviation (SD). Statistical analysis was analyzed with OriginPro 2016 via Students's t-test. The differences were considered significant for *P<0.05 and highly significant for **P<0.01.
Results and discussion Preparation and characterization of TiS 2 -HSA-Fa
TiS 2 nanosheets were first prepared by HSA-assisted ultrasonication, and their sheet structure was confirmed by AFM image ( Figure S1 ). They were then modified by PEGylated FA to produce TiS 2 -HSA-FA. TEM imaging shows that TiS 2 -HSA-FA has a sheet-like structure with a lattice plane spacing of 0.24 nm ( Figure 1A ). As shown in Figure 1B , the sharp and narrow XRD peaks in TiS 2 -HSA-FA indicate good crystallinity of the prepared TiS 2 -HSA-FA, consistent with observations from HRTEM ( Figure 1A, inset) . In addition, both bulk TiS 2 and TiS 2 -HSA-FA showed the same phase structure, demonstrating that the exfoliation process has no significant influence on the crystalline structure of the material. 37 According to DLS analysis, the zeta potential and average diameter of TiS 2 -HSA-FA nanoparticles were approximately −31.2 mVand 135.3 nm, respectively ( Figure 1C and D) . After 15 days of storage in physiological solution, the size of the TiS 2 -HSA-FA nanoparticles displayed no notable changes ( Figure 1E ). This stability is likely due to the absorption of HSA onto the surface of the particles, and subsequent modification with PEG. The UV-Vis spectrum of TiS 2 -HSA-FA in Figure 1F shows high absorbance across all wavelengths from UV to NIR. The extinction coefficient of TiS 2 -HSA-FA at 808 nm was found to be 30.1 L/g cm. In addition, as shown in Figure S2 , the more intense~1650 cm 
Cellular uptake and in vitro biocompatibility
After labeling by FITC, the behavior of TiS 2 -HSA and TiS 2 -HSA-FA in cells was tracked by fluorescence microscopy. The fluorescence images showed that cells treated with TiS 2 -HSA-FA showed much more fluorescence signal in cytoplasm than those treated with TiS 2 -HSA-FA + FA, TiS 2 -HSA, and free FITC ( Figure 3A) . ICP-AES quantitative analysis confirmed these results ( Figure 3B ). This indicates that FA conjugation significantly accelerated endocytosis of TiS 2 -HSA-FA. In addition, the in vitro biocompatibility of the TiS 2 -HSA-FA was evaluated by standard CCK-8 assay. As shown in Figure 3C , no significant cytotoxicity of TiS 2 -HSA-FA was found even at high concentrations up to 0.8 mg/mL, indicating good in vitro biocompatibility for both TiS 2 -HSA and TiS 2 -HSA-FA. In vitro synergistic PTT/RT
As shown in Figure 4A , CT26 cells treated with TiS 2 -HSA-FA showed 28.5°C of temperature increase after 5 mins of NIR laser irradiation (808 nm, 0.8 W/cm 2 ), which was higher than that of either TiS 2 -HSA-treated or control-treated cells. Since the data from Figure 2C suggested that TiS 2 has potential as a radiosensitizer, the in vitro RT efficacy of TiS 2 -HSA-FA was tested:
as seen in Figure 4B , cell viability decreased with increasing Xray dose. TiS 2 -HSA-FA + RT exhibited greater inhibition of cell viability than either TiS 2 -HSA-treated or control-treated cells. This is likely because TiS 2 -HSA-FA is more effectively endocytosed, and thus can absorb the energy of X-ray radiation more effectively inside tumor cells and channel it into the formation of secondary Auger electrons to damage DNA. Calcein-AM/PI staining and γ-H2AX immunofluorescence were further used to evaluate the combined effect of PTT and RT. The RT-and PTT-treated cells were stained by calcein-AM/ PI. As shown in Figure 4D , almost all the cells were killed in the TiS 2 -HSA-FA + NIR + RT group, while few were killed in the PBS, PBS + NIR, and TiS 2 -HSA-FA groups. Figure 4E shows the results of γ-H2AX immunofluorescence. In PBS + RT, PBS + NIR, TiS 2 -HSA-FA, and TiS 2 -HSA-FA + NIR-treated groups, negligible γ-H2AX immunofluorescence was seen. By contrast, the TiS 2 -HSA-FA + RT and TiS 2 -HSA-FA + NIR + RT-treated groups exhibited strong γ-H2AX immunofluorescence signals, suggesting that TiS 2 -HSA-FA can enhance the radio-sensitivity of cells and produce more DNA damage.
In vivo biodistribution and blood circulation
Titanium content of the major organs post-injection of TiS 2 -HSA and TiS 2 -HSA-FA were evaluated. The majority of the two nanoparticles were distributed in liver and kidney. Much more TiS 2 -HSA-FA was collected in tumor tissue than TiS 2 -HSA ( Figure 5A ). The concentration of TiS 2 -HSA-FA in tumor tissue peaked at 24 hrs post-injection ( Figure 5B ). The accumulation of TiS 2 -HSA-FA in tumor was likely due to the FA modification, which is known to facilitate tumor targeting. 44, 45 As shown in Figure 5C , after intravenous injection, blood distribution half-life (t 1/2 α) and blood terminal elimination half-life (t 1/2 β) of the TiS 2 -HSA-FA were 1.21±0.11 hrs and 17.52±0.62 hrs, respectively. It has been reported that PEG and HSA modifications can prolong blood circulation and reduce macrophage clearance of nanoparticles from the reticuloendothelial system.
46,47
In vivo synergistic PTT/RT After the treatment, the heart, liver, spleen, lung, kidney, and whole blood were collected for HE section staining and complete blood panel assays to evaluate the biocompatibility of the nanoparticles. As seen in Figure 8A and B, no obvious differences were observed between the TiS 2 -HSA-FA group and the control group. This indicates that TiS 2 -HSA-FA has good in vivo biocompatibility.
Conclusion
In summary, we have prepared a biocompatible PTT/RT nanoplatform TiS 2 -HSA-FA by using simple ultrasonication to create albumin exfoliated TiS 2 nanosheets that were then modified with PEG and FA. The TiS 2 -HSA-FA nanoparticles showed strong NIR light absorbance, good stability, and remarkable efficacy as a radio-sensitizer. In vitro and in vivo characterization showed TiS 2 -HSA-FA to have a high specificity for targeting tumors, likely due to its modification with FA. The nanoparticles also produced a remarkable, synergistic, cytotoxic effect under PTT/RT irradiation, and showed great biocompatibility in vitro and in vivo. This multifunctional nanoplatform shows great promise for future use as a new tumor therapeutic agent.
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